WTO's new rules allow poorest to import drugs

Eggertson, Laura
February 2006
CMAJ: Canadian Medical Association Journal;2/14/2006, Vol. 174 Issue 4, p444
Academic Journal
The article reports on a plan by the World Trade Organization (WTO) to legislate a waiver originally drafted in 2003, which would allow least-developed countries to import generic drugs in public health emergencies. The waiver pertains to Article 31 of the WTO Agreement on Trade-Related Aspects of Intellectual property Rights (TRIPS), requiring drugs to be sold in the domestic market of the countries that produce them. Médecins Sans Frontères criticizes the waiver.


Related Articles

  • Prescription Under the New York Generic Substitution Law. Francetic, Igor; Lasagna, Louis; Weintraub, Michael; Karch, Fred E. // Annals of Internal Medicine;Mar80, Vol. 92 Issue 3, p419 

    Evaluates the New York State generic substitution law which mandates substitution of a less expensive product if the physician signs the prescription for an eligible brand name drug. Options given by the law to the physician; Purpose of drug substitution; Assessment of prescription filling and...

  • The Generic Prescribing Issue. Brater, D. Craig; Pettinger, William A. // Annals of Internal Medicine;Mar80, Vol. 92 Issue 3, p426 

    Editorial. Comments on the issue facing the passage of generic drug substitution laws in the U.S. Goal of generic drug substitution laws; Need to consider the motives of both the proponents and opponents of the law in facing the issue; Analysis of who carries liability for the decision to...

  • Abu Dhabi moves towards generic prescribing.  // PharmaWatch: Monthly Review;Jun2009, Vol. 8 Issue 6, p39 

    The article reports on the move of the Health Authority of Abu Dhabi in United Arab Emirates towards prescription of generic drugs in the country. It notes that Health Authority of Abu Dhabi also forces doctors throughout the area to use generic drugs by molecular name. However, the law in the...

  • COMPETITION HEATS UP IN THE BIOLOGICS MARKET.  // Pharma Magazine;Jul/Aug2011, Vol. 7 Issue 4, p10 

    The article presents the author's insights on the emergence of biologic competition in the U.S. The author says that Big Pharma companies have invested on follow-on biologics to compete with multinational generic companies. He cites the impact of the U.S. biosimilar regulations to generics,...

  • Changes to India's patent law may deny cheap drugs to millions. Mudur, Ganapati // BMJ: British Medical Journal (International Edition);3/26/2005, Vol. 330 Issue 7493, p692 

    Looks at changes to patent laws in India which will impact the availability of generic drugs. Actions of the Indian parliament to introduce patents for medication, which will make cheaper generic drugs unavailable; Alignment of the proposed law with international standards for intellectual...

  • AMCP objects.  // Drug Topics;5/19/97, Vol. 141 Issue 10, p25 

    Reports that the Academy of Managed Care Pharmacy has signified its opposition to proposed legislation restricting generic substitution for certain drugs.

  • N.J. companies warn Assembly on cost of bill.  // Drug Store News;7/14/97, Vol. 19 Issue 11, pCP3 

    Reports that various generic pharmaceutical companies based in New Jersey have sent letters to the New Jersey Assembly urging members to defeat a bill restricting generic substitutions in the state.

  • Governor approves NTI restrictions on generics.  // Drug Store News;7/14/97, Vol. 19 Issue 11, pCP8 

    Reports that North Carolina's governor has signed into law a bill that limits the right of pharmacists to substitute generics.

  • Chains react swiftly to pending reimbursement cuts.  // Chain Drug Review;4/26/2010, Vol. 32 Issue 8, p6 

    The article reports on the opposition of the drug store companies in Ontario to the legislation on reducing the reimbursement rate of generic drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics